Recurrent Ovarian Cancer Clinical Trials
Links shared publicly online about this topic
Ovarian cancer vaccine: Can it prevent recurrence? - MayoClinic.com
mayoclinic.com — “Research continues to evaluate the role of an ovarian cancer vaccine to prevent recurrence.” View full resource at mayoclinic.com
Most Recently Shared on March 24, 2012 at 2:20 am By:
Julie Bohlen Health Executive and Active Health Library
Ovarian cancer vaccine: Can it prevent recurrence?: Research continues to evaluate the role of an ovarian cancer... http://t.co/fbwU0zDZ
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - ONA
oncologynurseadvisor.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 7, 2010 at 8:20 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer http://goo.gl/fb/vAkMj
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - MPR
empr.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at empr.com
Most Recently Shared on June 7, 2010 at 8:14 pm By:
MPR News: Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer: Amgen announced that AMG 386, combin... http://bit.ly/cBbIUj
EGEN, Inc. Announces That Phase II Clinical Trial For Advanced Ovarian Cancer Is Open For Enrollment
medicalnewstoday.com — “EGEN, Inc. announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment. The trial is sponsored by the Gynecologic” View full resource at medicalnewstoday.com
Most Recently Shared on December 15, 2010 at 6:05 pm By:
MNT Ovarian Cancer Health News
EGEN, Inc. Announces That Phase II Clinical Trial For Advanced Ovarian Cancer Is Open For Enrollment http://mnt.to/3P6r #ovariancancer
MabCure Launches Clinical Trial To Diagnose Ovarian Cancer
medicalnewstoday.com — “Mabcure, n.v. (mabcure) a wholly-owned subsidiary of mabcure inc. (otcbb: mbci) , a biotech company that has developed a series of highly specific monoclonal antibodies (mabs) to combat various ” View full resource at medicalnewstoday.com
Most Recently Shared on January 8, 2010 at 9:18 am By:
MabCure Launches Clinical Trial To Diagnose Ovarian Cancer http://mnt.to/3w47
Commencement Of A Phase II Clinical Trial Of SG2000 In Ovarian Cancer
medicalnewstoday.com — “Spirogen Limited (the Company) and Celtic Therapeutics Holdings LP (Celtic Therapeutics) announced the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is bein” View full resource at medicalnewstoday.com
Most Recently Shared on September 16, 2010 at 2:00 pm By:
MNT Ovarian Cancer Health News
Commencement Of A Phase II Clinical Trial Of SG2000 In Ovarian Cancer http://mnt.to/3JQh #ovariancancer
Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer
medicalnewstoday.com — “Ovarian cancer is a major health concern for women and the identification of sensitive biomarkers for early detection and/or monitoring of disease recurrence is of high clinical relevance.” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2011 at 9:07 am By:
MNT Ovarian Cancer Health News
Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer http://t.co/7OgdD8rC #ovariancancer
GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer
news-medical.net — “Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.” View full resource at news-medical.net
Most Recently Shared on November 1, 2010 at 4:49 pm By:
Lung Cancer News: GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer: Syn... http://bit.ly/91GDOX
Upcoming Webinar: How Can I Get Involved in Ovarian Cancer Clinical Trials? | Ovarian Cancer National Alliance
ovariancancer.org — “This 90-minute session will cover the basics of cancer clinical trials, including key risks and benefits, myths about clinical trials and how people can be” View full resource at ovariancancer.org
Most Recently Shared on March 31, 2011 at 9:27 pm By:
Paul Cacciatore Patient Advocate
Upcoming OCNA Webinar: How Can I Get Involved in Ovarian Cancer Clinical Trials? http://dld.bz/U6ye
Ovarian Cancer Home Page
cancer.gov — “Information about ovarian cancer treatment, prevention, genetics, causes, screening, clinical trials, research and statistics from the National Cancer Institute.” View full resource at cancer.gov
Most Recently Shared on July 30, 2009 at 7:38 pm By:
Pacific Oncology Physician Group
Estimated new cases and deaths from ovarian #cancer in the United States in 2010: New cases: 21,880 Deaths:... http://fb.me/G63kERqr
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - MPR
empr.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.” View full resource at empr.com
Most Recently Shared on June 5, 2011 at 6:53 pm By:
#asco2011 Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in… http://goo.gl/fb/MUWQq
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - ONA
oncologynurseadvisor.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 5, 2011 at 6:30 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent… http://goo.gl/fb/oUkM7
Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability - ONA
oncologynurseadvisor.com — “The combination of oxaliplatin and doxorubicin showed promising efficacy in either platinum-sensitive or platinum-resistant recurrent ovarian cancer, as reported by Ilya Pokateav, MD, from the Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, and colleagues at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 5, 2011 at 5:23 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability http://goo.gl/fb/ldXlW
Medical News: SGO: Drug Combination Slows Recurrent Ovarian Cancer - in Meeting Coverage, SGO from MedPage Today
medpagetoday.com — “SAN FRANCISCO -- Combination chemotherapy resulted in a longer, progression-free survival (PFS) than did sequential therapy in a randomized clinical trial of patients with recurrent, platinum-sensitiv” View full resource at medpagetoday.com
Most Recently Shared on March 15, 2010 at 2:41 pm By:
SGO: Drug Combination Slows Recurrent Ovarian Cancer (CME/CE) SAN FRANCISCO (MedPage Today) -- Combination chemothera.. http://bit.ly/bNbtkZ
Ovarian Cancer Drug Shows Promise With Move To Phase 3 Trial
medicalnewstoday.com — “A new drug designed to arrest cancer cell growth by inhibiting blood vessel formation in ovarian cancer patients is being readied for a phase 3 trial in Australia, Canada and Europe. The” View full resource at medicalnewstoday.com
Most Recently Shared on November 10, 2010 at 6:05 pm By:
MNT Ovarian Cancer Health News
Ovarian Cancer Drug Shows Promise With Move To Phase 3 Trial http://mnt.to/3MmS #ovariancancer
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Julie Bohlen
Health content professional with MBA in heathcare management. Sharing quality health resources and news. On executive team at OrganizedWisdom.
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
